FTO affects food cravings and interacts with age to influence age-related decline in food cravings

Linh C. Dang¹, Gregory R. Samanez-Larkin², Christopher T. Smith¹, Jaime J. Castrellon², Scott F. Perkins¹, Ronald L. Cowan³,⁴, Daniel O. Claassen⁵, and David H. Zald¹,³

1. Department of Psychology, Vanderbilt University
   219 Wilson Hall, 111 21st Avenue South, Nashville, TN 37203

2. Department of Psychology and Neuroscience, Duke University
   417 Chapel Drive, Campus Box 90086, Durham, NC 27708

3. Department of Psychiatry and Behavioral Sciences, Vanderbilt University
   School of Medicine
   1601 23rd Ave South, Nashville, TN 37212

4. Department of Radiology and Radiological Sciences, Vanderbilt University
   Medical Center
   1211 Medical Center Drive, Nashville, TN 37232

5. Department of Neurology, Vanderbilt University Medical Center
   1211 Medical Center Drive, Nashville, TN 37232

Corresponding author:
Linh C. Dang, Ph.D.
Department of Psychology, Vanderbilt University
23  219 Wilson Hall
24  111 21\textsuperscript{st} Avenue South
25  Nashville, TN  37203
26  Email: linh.dang@vanderbilt.edu
27  Phone: 1-615-322-5265
28
**Highlights**

- FTO is associated with differences in body mass index (BMI) and odds of obesity.
- Present results showed FTO rs9939609 A allele correlating with higher food craving.
- Higher food craving correlated with higher BMI.
- Carriers of A allele did not show the typical age-related decline in food craving.
- No evidence of FTO effects on dopamine D2 receptor availability.
The fat mass and obesity associated gene (FTO) was the first gene identified by genome-wide association studies to correlate with higher body mass index (BMI) and increased odds of obesity. FTO remains the locus with the largest and most replicated effect on body weight, but the mechanism whereby FTO affects body weight and the development of obesity is not fully understood. Here we tested whether FTO is associated with differences in food cravings and a key aspect of dopamine function that has been hypothesized to influence food reward mechanisms. Moreover, as food cravings and dopamine function are known to decline with age, we explored effects of age on relations between FTO and food cravings and dopamine function. Seven-eight healthy subjects between 22 and 83 years old completed the Food Cravings Questionnaire and underwent genotyping for FTO rs9939609, the first FTO single nucleotide polymorphism associated with obesity. Compared to TT homozygotes, individuals carrying the obesity-susceptible A allele had higher total food cravings, which correlated with higher BMI. Additionally, food cravings declined with age, but this age effect differed across variants of FTO rs9939609: while TT homozygotes showed the typical age-related decline in food cravings, there was no such decline among A carriers. All subjects were scanned with [18F]fallypride PET to assess a recent proposal that at the neurochemical level FTO alters dopamine D2-like receptor (DRD2) function to influence food reward related mechanisms. However, we observed no evidence of FTO effects on DRD2 availability.
Keywords: FTO, food cravings, aging, dopamine receptor availability
Introduction

Studies of heritability have found that genetic differences explain 40% to 70% of the variance in individual susceptibility to obesity (Maes et al., 1997; Elks et al., 2012), which affects more than 10% of the world’s population (Collaborators et al., 2017). In 2007, the fat mass and obesity associated gene (FTO) became the first gene identified by genome-wide association studies to correlate with higher body mass index (BMI) and increased odds of obesity (Frayling et al., 2007; Scuteri et al., 2007). Subsequent genome-wide studies have linked other loci with obesity susceptibility, but FTO remains the locus with the largest effect (Speliotes et al., 2010) and is the most widely replicated across ethnic groups (Lu and Loos, 2013). The risk allele is also common, with the minor allele frequency ranging from 12% in East Asians to 42% in Europeans (Li et al., 2012). The mechanism whereby FTO affects body weight and the development of obesity is not well understood, but evidence to date suggests a role for FTO in adipogenesis, energy metabolism, and nutrient intake (Yang et al., 2017).

It has also been proposed that FTO influences food reward mechanisms. Individuals with at least one A allele of FTO rs9939609 (the first FTO single nucleotide polymorphism associated with obesity) have been reported to show greater externally driven eating (Velders et al., 2012), lowered satiety (Wardle et al., 2008; den Hoed et al., 2009), enhanced fMRI response to food (Karra et al., 2013), and report more frequent loss of control over eating than those having two T alleles (Tanofsky-Kraff et al., 2009). The control of eating is particularly hard in the context of heightened food cravings (Hill, 2007), but little data have
addressed whether FTO rs9939609 is associated with alterations in food cravings. One study (Huang et al., 2014) observed no relation between FTO and participants’ responses on one question about how often they experienced cravings in the previous week, but there was an indication of a possible interaction between FTO and diet on the change in craving from baseline to 6 months after participating in a weight loss program, with evidence of an FTO effect only arising in those with high protein intake. In evaluating such a result, it is worth noting that food craving is a multidimensional construct (Cepeda-Benito et al., 2000). It is not clear which aspects of craving this single-question test captured and how different aspects of cravings relate to FTO. It is also unclear whether the restriction of the sample to overweight and obese subjects impacted the ability to observe effects.

Given the importance of dopamine to reward and addictive behavior (Di Chiara and Bassareo, 2007), it is striking that at the neurochemical level, mice with deficient FTO expression exhibit characteristics similar to mice lacking midbrain dopamine D2 receptors (DRD2) (Bello et al., 2011; Hess et al., 2013). Moreover inactivation of the FTO gene impaired DRD2-dependent neuronal and reward responses in mice, though the study did not observe a significant difference in body weight or DRD2 expression between FTO-deficient and control mice (Hess et al., 2013). Still, other evidence of FTO effects on dopamine-dependent reward learning (Sevgi et al., 2015) and resting state functional connectivity in dopaminergic circuitries (Olivo et al., 2016) has led to the recent proposal that FTO alters DRD2 function in the presence of an obesogenic diet to
confer risk for obesity (Sun et al., 2017). Evidence of an association between FTO and DRD2 function in humans would further support this hypothesis. Potential relations between FTO, cravings, and DRD2 availability must unfold in the context of life-span development. Fat mass is well-known to increase across adulthood (St-Onge, 2005) and at least one FTO risk gene (rs1421085) has been reported to impact the trajectory of weight gain as well as personality traits and ventral and medial prefrontal brain functions (Chuang et al., 2015). At the neurochemical level, the most replicated finding in the dopamine imaging literature is the robust decline in DRD2 availability across adulthood (Ichise et al., 1998; Karrer et al., 2017). We recently reported that associations between DRD2 and BMI change with age (Dang et al., 2016). Finally, both the intensity of craving and the number of foods craved decline with age (Antonini et al., 1993; Pelchat, 1997; Ichise et al., 1998). It is not yet known whether FTO influences the age-related decline in either food cravings or DRD2. However, given the developmental trajectories of these phenotypic variables, it is important to determine whether any potential relations with FTO vary or interact with age.

The present study had three objectives. First, we examined the role of FTO rs9939609 in food cravings in individuals spanning the BMI continuum from normal weight to obese. Nine dimensions of food cravings were assessed using the psychometrically validated Food Cravings Questionnaire (Cepeda-Benito et al., 2000) to understand the specificity of the relation between FTO rs9939609 and food cravings. Second, we tested the hypothesis that FTO influences DRD2 availability, assessed using PET and the high-affinity DRD2 radioligand
Lastly, we explored effects of age on the relation between FTO, food cravings, and DRD2 to determine whether expected age-related declines in food cravings and DRD2 availability vary across FTO rs9939609 allele groups. The results of these inquiries may shed light on possible mechanisms whereby FTO influences body weight that can be utilized to facilitate greater specificity for therapies combatting obesity.

Methods

Subjects

Seventy-eight healthy subjects between 22 and 83 years old (mean age 49.9±18.0 years, 46 females, mean BMI 27.0±5.1) from the Nashville, TN metro area were recruited to participate in this study. Exclusion criteria included any history of psychiatric illness on a screening interview (a Structural Interview for Clinical DSM-IV Diagnosis was also available for all subjects and confirmed no history of major Axis I disorders) (First et al., 1997), any history of head trauma, any significant medical condition, or any condition that would interfere with MRI (e.g. inability to fit in the scanner, claustrophobia, cochlear implant, metal fragments in eyes, cardiac pacemaker, neural stimulator, pregnancy, and metallic body inclusions or other contraindicated metal implanted in the body). Subjects with major medical disorders including diabetes and/or abnormalities on screening comprehensive metabolic panel or complete blood count were excluded. Subjects were also excluded if they reported a history of substance abuse, current tobacco use, alcohol consumption greater than 8 ounces of
whiskey or equivalent per week, use of psychostimulants (excluding caffeine)
more than twice at any time in their life or at all in the past 6 months, or any
psychotropic medication in the last 6 months other than occasional use of
benzodiazepines for sleep. Any illicit drug use in the last 2 months was grounds
for exclusion, even in subjects who did not otherwise meet criteria for substance
abuse. Urine drug tests were administered, and subjects testing positive for the
presence of amphetamines, cocaine, marijuana, PCP, opiates, benzodiazepines,
or barbiturates were excluded. Written informed consent was obtained from all
subjects. This study was approved by the Institutional Review Boards at Yale
University and Vanderbilt University and performed in accordance with the ethical
standards of the 1964 Declaration of Helsinki and its later amendments. Data are
available at the Open Science Framework.

Genotyping of FTO
Blood samples from each subject were genotyped for FTO rs9939609 via
Sequenom analysis performed at Vanderbilt University’s VANTAGE Genomics
Core (see Ritchie et al., 2010 for detailed Sequenom genotyping methods).

Food Cravings Questionnaire – Trait version
The Food Cravings Questionnaire assesses motivational states that
promote food cravings and ingestive behaviors and has been demonstrated to
possess good internal consistency and test-retest reliability (Cepeda-Benito et
al., 2000). The self-report questionnaire consists of 39 questions assessing 9
dimensions of food cravings: 1) having intentions or plans to consume food, 2) anticipation of positive reinforcement that may result from eating, 3) anticipation of relief from negative states and feelings as a result of eating, 4) lack of control over eating, 5) thoughts or preoccupation with food, 6) cravings as a physiological state, 7) emotions that may be experienced before or during food cravings or eating, 8) cues that may trigger food cravings, and 9) guilt from cravings and/or for giving into them.

PET data acquisition

PET imaging was performed on a GE Discovery STE scanner located at Vanderbilt University Medical Center. The scanner had an axial resolution of 4 mm and in-plane resolution of 4.5-5.5 mm FWHM at the center of the field of view. [18F]fallypride ((S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3[18F]fluoropropyl)-2,3-dimethoxybenzamide) was produced in the radiochemistry laboratory attached to the PET unit, following synthesis and quality control procedures described in US Food and Drug Administration IND 47,245. [18F]fallypride is a substituted benzamide with very high affinity to D2/D3 receptors (Mukherjee et al., 1995). 3D emission acquisition scans were performed following a 5.0 mCi slow bolus injection of [18F]fallypride (specific activity greater than 3000 Ci/mmol). CT scans were collected for attenuation correction prior to each of the three emission scans, which together lasted approximately 3.5 hours, with two 15-minute breaks for subject comfort. PET images were reconstructed with decay correction, attenuation correction, scatter correction, and calibration.
MRI data acquisition

Structural MRI scans were performed on a 3 Tesla Phillips Achieva scanner located at the Vanderbilt University Institute for Imaging Science (VUIIS). T1-weighted high-resolution 3D anatomical scans (TR=8.9ms, TE=4.6ms, FOV=256x256, voxel dimensions=1×1×1mm) were obtained for each participant to aid coregistration and spatial normalization of PET images.

[18F]fallypride binding potential (BP_{ND}) image calculation

Voxelwise D2/D3 binding potential images were calculated using the simplified reference tissue model, which has been shown to provide stable estimates of [18F]fallypride BP_{ND} (Siessmeier et al., 2005). The cerebellum served as the reference region because of its relative lack of D2/D3 receptors (Camps et al., 1989). The cerebellar reference region was obtained from an atlas provided by the ANSIR laboratory at Wake Forest University. Limited PET spatial resolution introduces blurring and causes signal to spill onto neighboring regions. Because the anterior cerebellum is located proximal to the substantia nigra and colliculus, which both have DRD2, only the posterior 3/4 of the cerebellum was included in the region of interest (ROI) to avoid contamination of [18F]fallypride signal from the midbrain nuclei. The cerebellum ROI also excluded voxels within 5mm of the overlying cerebral cortex to prevent contamination from cortical signals. The bilateral putamen ROI, drawn according to established guidelines (Mawlawi et al., 2001) on the MNI brain, served as the receptor rich region in the
The cerebellum and putamen ROIs were registered to each subject’s T1 image using FSL non-linear registration of the MNI template to each individual subject’s T1. T1 images and their associated cerebellum and putamen ROIs were then coregistered to the mean image of all realigned frames in the PET scan using FSL-FLIRT (http://www.fmrib.ox.ac.uk/fsl/, version 6.00). Emission images from the 3 PET scans were merged temporally into a 4D file. To correct for motion during scanning and misalignment between the 3 PET scans, all PET frames were realigned using SPM8 (www.fil.ion.ucl.ac.uk/spm/) to the frame acquired 10 minutes post injection. Model fitting and BPND calculation were performed using the PMOD Biomedical Imaging Quantification software (PMOD Technologies, Switzerland). Binding potential images represent the ratio of specifically bound ligand ([18F]fallypride in this study) to its free concentration (Fig. 1).

Mean BPND in the striatum, which has the highest concentration of postsynaptic DRD2 in the brain, and the midbrain, the site of dopamine neurons on which presynaptic DRD2 are located, were extracted to test for association with FTO rs9939609. The bilateral midbrain and 3 striatal ROIs (caudate, putamen, and ventral striatum / nucleus accumbens) were drawn in MNI standard space using previously described guidelines (Fig. 1) (Mawlawi et al., 2001; Dang et al., 2012), registered to PET images using the same transformations for cerebellum registration to PET images, and thresholded at 0.5 after coregistration to exclude voxels on the border that had less than 50% probability of being part of the ROI, thus ensuring high tissue probability for each
ROI masks. Relations between FTO rs9939609 and BP\textsubscript{ND} outside the striatum and midbrain were examined with an exploratory voxelwise analysis.

Results

**FTO rs9939609 and food cravings**

There were 10 AA homozygotes, 40 AT heterozygotes, and 28 TT homozygotes. The allele frequencies were in Hardy-Weinberg equilibrium ($\chi^2=0.542$, $p>0.4$). There was no difference in age or gender composition between TT homozygotes and individuals carrying at least one A allele.

Compared to TT homozygotes, A carriers had higher total food cravings score (Fig. 2A). We explored the specificity of FTO effects on food cravings by examining the role of FTO in each of the nine dimensions of food cravings. At the significance level corrected for multiple comparisons of nine dimensions (p<0.006), A carriers scored higher than TT homozygotes on 3 dimensions: anticipation of relief from negative states and feelings as a result of eating, having intentions or plans to consume food, and emotions that may be experienced before or during food cravings or eating. A carriers also scored higher on 2 other dimensions at the uncorrected significance level (p<0.05): anticipation of positive reinforcement that may result from eating and thoughts or preoccupation with food. There were trends (p<0.1) for A carriers having higher guilt from cravings and/or for giving into them and lack of control over eating. There was no difference between TT homozygotes and A carriers in responses to cues that may trigger food cravings and cravings as a physiological state.
These results did not change when we controlled for age, gender, and BMI.

**Total food cravings and BMI**

Total food craving scores positively associated with BMI ($\beta=0.26$, $t_{74}=2.236$, $p<0.05$), controlling for age and gender. However, as seen in Figure 2B, this association was driven by 3 participants with BMI in the Obese class III category ($\geq 40$), and was weaker without these 3 participants ($\beta=0.20$, $t=1.71$, $p<0.1$). Unexpectedly, BMI did not significantly associate with FTO rs9939609 ($\beta=0.04$, $t_{71}=0.324$, $p>0.7$).

**Effects of age on FTO rs9939609 and total food cravings**

As expected, food cravings declined with increasing age ($r_{76}=-0.28$, $p<0.05$) (Fig. 3A). Furthermore, age interacted with FTO to predict food cravings ($\beta=0.70$, $t=2.06$, $p<0.05$). Food cravings declined with age among TT homozygotes ($r_{26}=-0.51$, $p<0.01$), but among A carriers, there was no significant correlation between food cravings and age ($r_{48}=-0.13$, $p>0.3$) (Fig. 3B). Results did not change after controlling for gender and BMI.

**FTO rs9939609 and DRD2 availability**

There was no significant difference between TT homozygotes and A carriers in [18F]fallypride $\text{BP}_{\text{ND}}$ in the midbrain or striatum: caudate, putamen, and ventral striatum (Fig. 4) (Table 1). Voxelwise analysis did not identify any
significant difference between TT homozygotes and A carriers in \( BP_{\text{ND}} \) outside the striatum and midbrain, in addition to confirming the lack of such association in the striatum and midbrain, even at the liberal voxel-level threshold of \( p<0.001 \) uncorrected for multiple comparisons. Sun et al. (2017) proposed that FTO interacts with an obesogenic diet to alter DRD2 function and consequently body weight, suggesting that the relation between FTO and DRD2 might be more discernable among obese individuals. There were 18 subjects with BMI greater than 30 in the present sample. We reanalyzed the data with only these 18 subjects and again observed no relation between FTO rs9939609 and DRD2 availability in the midbrain or striatum (all \( p>0.5 \), all \( |r|<0.12 \)). \([18F]\)fallypride \( BP_{\text{ND}} \) declined with age as expected (all \( r<-0.48 \), all \( p<0.00001 \)), but there was no significant interaction of age and FTO rs9939609 on \( BP_{\text{ND}} \) (all \( p>0.1 \), all \( |r|<0.17 \)). Food cravings did not correlate with \([18F]\)fallypride \( BP_{\text{ND}} \) in the striatum or midbrain (all \( p>0.1 \), all \( |r|<0.16 \)). Additionally FTO rs9939609 did not significantly interact with \([18F]\)fallypride \( BP_{\text{ND}} \) in the striatum or midbrain to predict food cravings (all \( p>0.1 \), all \( |r|<0.18 \)). Results controlled for gender and age.

Discussion

Among individuals spanning the BMI continuum from normal weight to obese, those with at least one FTO rs9939609 obesity-susceptible A allele, relative to TT homozygotes, reported higher food cravings. This relation remained after controlling for BMI, suggesting that FTO rs9939609 influences food cravings independent of individual differences in BMI. These results are
congruent with a previous finding that individuals with the A allele reported higher lack of control over eating, which positively correlates with food cravings (Hill, 2007; Tanofsky-Kraff et al., 2009). Of the nine dimensions of food cravings, FTO rs9939609 was most strongly associated with emotions (predominantly negative) that may be experienced before or during food cravings or eating, the anticipation of relief from negative states and feelings as a result of eating, and having intentions or plans to consume food. These three dimensions suggest that FTO rs9939609 particularly influences processes that promote food and food seeking behavior as a countermeasure to negative states. Interestingly, the two dimensions not associated with FTO rs9939609 (cravings as a physiological state and cues that may trigger food cravings) are the two dimensions that involve sensory cues, such as external food cues and physiological sensations. This specificity of FTO rs9939609 effects on food cravings suggests that FTO rs9939609 influences the cognitive and motivational, rather than sensory, processes involved in food cravings. The specificity of observed FTO rs9939609 effects may explain a previous study’s observation of no relation between FTO rs9939609 and response on one question about recent craving frequency (Huang et al., 2014) as this unvalidated generic question may have been too general to capture features of craving related to FTO rs9939609. We note that our suggestion that FTO has less impact on responses to sensory cues in our adult sample stands in contrast to a past finding that the FTO risk allele was associated with parental report of enhanced food responsiveness (eating when food is available) in children (Velders et al., 2012). This may reflect differences in
constructs across measures or a developmental difference. Responses to reward mature over development from lower-order sensory processing in subcortical and limbic regions to higher-order processing in frontal cortical brain areas that allow integration of valuation and top-down goal driven behavior (Killgore and Yurgelun-Todd, 2005), and so the impact of FTO may be developmentally specific.

Consistent with the extant literature, food cravings declined across adulthood. Our results further demonstrated that FTO rs9939609 interacted with age to predict food cravings. Among TT homozygotes, food cravings declined with age as previously reported. However, among individuals carrying the obesity-susceptible A allele, there was no significant decline in food cravings with age. This preservation of food cravings across adulthood may be specific to craving for fat, rather than protein or carbohydrate, as age-related decline in fat intake has been found significantly reduced among A carriers (Chuang et al., 2015). Given the positive association between food cravings and BMI, in our data and as previously shown (Franken and Muris, 2005), these results suggest that individuals carrying the A allele are at risk for larger weight gain over the course of aging as fat mass in the body often increases with age (Ogden et al., 2006).

We note that FTO rs9939609 did not associate with BMI in this sample. Genome-wide studies found the relation between FTO and BMI by scanning the genome of tens of thousands of subjects, and the effects have been replicated (Loos and Yeo, 2014). It is possible that the lack of effect here just reflects low statistical power, but we cannot rule out that selection biases, such as the requirement that
all subjects be medically and psychiatrically healthy, with no contraindications for scanning and willing to participate, may have limited our ability to observe an effect. The lack of an FTO effect on BMI in this sample strongly suggests that FTO effects on craving are not a consequence of differential BMI across groups.

We explored the proposal that FTO modulates DRD2 function to influence body weight. Using PET-[18F]fallypride to assess DRD2 availability, we did not observe any significant association between FTO rs9939609 and DRD2 availability, nor any relation between DRD2 availability and food cravings. Sun et al. (2017) hypothesized that FTO interacts with an obesogenic diet to alter DRD2 function and body weight, suggesting that the relation between FTO and DRD2 might be more discernable among obese individuals. We also did not observe any relation between FTO rs9939609 and DRD2 availability among participants with BMI greater than 30. Besides DRD2 availability, there are other characteristics of DRD2 function such as receptor affinity, susceptibility to desensitization, and responsiveness to up/down regulation (Cooper et al., 2003). Our data did not speak to the relation between FTO rs9939609 and these specific aspects of DRD2 function. Additionally, although rs9939609 is the first single nucleotide polymorphism in the FTO gene associated with obesity, other FTO single nucleotid polymorphisms have been linked to obesity since then and it is not known whether other FTO single nucleotide polymorphisms affect DRD2 function. Nonetheless, until there is evidence showing FTO effects on DRD2 function in humans, the present results suggest caution in translating such effects in mice to FTO function in humans.
It is worth noting that our finding of a positive correlation between food cravings and BMI was weaker without 3 Obese class III participants, and that a previous study did not observe a relation between FTO rs9939609 and food craving in obese individuals (Huang et al., 2014). These results suggest that obese subjects may represent a distinct category with different relationships between FTO, food cravings, and BMI. Future studies with sufficient number of obese and non-obese participants would provide clarity. Moreover the present study excluded individuals with major medical conditions including those associated with obesity, such as diabetes. Individuals with obesity-related medical conditions may also represent another category from individuals without these medical conditions in the context of FTO. We additionally note that FTO effects on BMI vary across ethnicities (Loos and Yeo, 2014), and this may impact relations between FTO and food cravings in different ethnic groups. While FTO effect size is similar among individuals of Asian and European descents, the frequency of the FTO obesity-susceptible A allele is much lower among Asians than Europeans. Also, relative to Europeans, African-Americans exhibit lower correlations between different FTO single nucleotide polymorphisms linked to obesity, and this may impact FTO associations with obesity traits (Loos and Yeo, 2014). The present study did not have sufficient representation of different ethnic groups to address the role of ethnicity in FTO effects.

A clear limitation of this study is the small sample size, which was necessitated by the expense, time, and safety demands of PET imaging. Although this study had the advantage of testing specific hypotheses of FTO
function, genomic studies often involve tens, if not hundreds, of thousands of subjects, because single gene effects are typically modest. This naturally suggests caution in interpreting underpowered analyses. Additionally, although the wide age range in this study allowed an examination of age effects on FTO function, it also introduced a variable that might have obscured the ability to detect some FTO effects, which could explain the lack of a relation between FTO rs9939609 and BMI in this study even though this association has been reported by multiple researchers.

In conclusion, the present results showed that relative to FTO rs9939609 TT homozygotes, individuals with at least one A allele reported greater food cravings, which positively correlated with BMI. A carriers also did not show the typical age-related decline in food cravings, suggesting that they are at risk for larger weight gain over the course of aging as fat mass often increases with age. While these conclusions are limited by the small sample size, and do not indicate the precise mechanism through which FTO influences food craving, we hope that the present findings encourage future studies to examine FTO’s impact on food craving in a broader sample.

Conflict of interest

All authors report no conflict of interest.

Acknowledgements
This work was supported by the National Institute on Aging (R01AG044838 to DHZ, R00AG042596 to GRSL) and the National Institute on Drug Abuse (F32DA036979 to LCD).
Figure captions

Fig 1. [18F]fallypride BP_{ND} images reflecting DRD2 availability. A) Shown are regions of interest from which mean BP_{ND} were extracted for analyses: caudate (blue), putamen (green), ventral striatum (yellow), and midbrain (red). B) Example of a [18F]fallypride BP_{ND} image showing high BP_{ND} in the striatum (top) and midbrain (bottom).

Fig 2. FTO, food cravings, and BMI. A) Compared to TT homozygotes, A carriers had higher total food cravings (t_{76}=3.02, p<0.01). B) Food cravings were positively associated with BMI (t_{74}=2.236, p<0.05).

Fig 3. FTO-age interaction on food cravings. A) Food cravings declined with age across all subjects (r_{76}=-0.28, p<0.05). B) Among TT homozygotes, food cravings declined with age (r_{26}=-0.51, p<0.01) (red), but among A carriers, there was no significant correlation between food cravings and age (r_{48}=-0.13, p>0.3) (blue).

Fig 4. FTO and DRD2 availability. No significant difference between TT homozygotes and A carriers in [18F]fallypride BP_{ND} in the A) caudate (t_{76}=0.33, p>0.5), B) putamen (t_{76}=0.51, p>0.5), C) ventral striatum (t_{76}=-0.07, p>0.5), or D) midbrain (t_{76}=0.62, p>0.5).
References


### Table 1: Demographics, food cravings scores, and [18F]fallypride BP

<table>
<thead>
<tr>
<th></th>
<th>A carriers</th>
<th>TT homozygotes</th>
<th>t76</th>
<th>p-value</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>50</td>
<td>28</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (yrs)</td>
<td>49.0 ± 18.5</td>
<td>51.6 ± 17.2</td>
<td>0.60</td>
<td>0.551</td>
<td>-5.94, 11.04</td>
</tr>
<tr>
<td>Gender</td>
<td>29F</td>
<td>17F</td>
<td>0.23</td>
<td>0.818</td>
<td></td>
</tr>
<tr>
<td>Total craving score</td>
<td>95.3 ± 19.5</td>
<td>80.2 ± 23.8</td>
<td>3.02</td>
<td>0.003**</td>
<td>5.11, 24.98</td>
</tr>
<tr>
<td>Planning</td>
<td>8.4 ± 2.3</td>
<td>6.7 ± 2.3</td>
<td>3.10</td>
<td>0.003**</td>
<td>0.60, 2.77</td>
</tr>
<tr>
<td>Pos Reinforcement</td>
<td>13.4 ± 3.6</td>
<td>11.2 ± 3.4</td>
<td>2.63</td>
<td>0.010*</td>
<td>0.53, 3.84</td>
</tr>
<tr>
<td>Neg Relief</td>
<td>7.2 ± 2.1</td>
<td>5.6 ± 2.1</td>
<td>3.13</td>
<td>0.003**</td>
<td>0.57, 2.58</td>
</tr>
<tr>
<td>Lack Control</td>
<td>12.9 ± 4.4</td>
<td>11.1 ± 4.2</td>
<td>1.73</td>
<td>0.088</td>
<td>-0.27, 3.81</td>
</tr>
<tr>
<td>Thoughts</td>
<td>13.2 ± 4.4</td>
<td>10.9 ± 4.0</td>
<td>2.31</td>
<td>0.024*</td>
<td>0.32, 4.36</td>
</tr>
<tr>
<td>Hunger</td>
<td>11.4 ± 2.8</td>
<td>10.7 ± 2.7</td>
<td>0.98</td>
<td>0.331</td>
<td>-0.67, 1.96</td>
</tr>
<tr>
<td>Emotion</td>
<td>9.6 ± 3.4</td>
<td>7.3 ± 3.2</td>
<td>2.88</td>
<td>0.005**</td>
<td>0.70, 3.85</td>
</tr>
<tr>
<td>Environment</td>
<td>11.5 ± 3.7</td>
<td>10.1 ± 4.0</td>
<td>1.54</td>
<td>0.127</td>
<td>-0.41, 3.20</td>
</tr>
<tr>
<td>Guilt</td>
<td>7.7 ± 2.6</td>
<td>6.6 ± 2.6</td>
<td>1.94</td>
<td>0.056</td>
<td>-0.03, 2.37</td>
</tr>
<tr>
<td>Caudate BP(_{ND})</td>
<td>13.8 ± 3.6</td>
<td>13.5 ± 3.6</td>
<td>0.33</td>
<td>0.743</td>
<td>-1.42, 1.97</td>
</tr>
<tr>
<td>Putamen BP(_{ND})</td>
<td>23.2 ± 3.5</td>
<td>22.7 ± 3.8</td>
<td>0.51</td>
<td>0.613</td>
<td>-1.27, 2.13</td>
</tr>
<tr>
<td>Ventral striatal BP(_{ND})</td>
<td>14.0 ± 2.5</td>
<td>14.0 ± 2.8</td>
<td>-0.07</td>
<td>0.941</td>
<td>-1.25, 1.16</td>
</tr>
<tr>
<td>Midbrain BP(_{ND})</td>
<td>1.2 ± 0.2</td>
<td>1.2 ± 0.2</td>
<td>0.62</td>
<td>0.540</td>
<td>-0.07, 0.13</td>
</tr>
</tbody>
</table>

**corrected for multiple comparisons, *uncorrected

Note: Planning = having intentions or plans to consume food; Pos Reinforcement = anticipation of positive reinforcement that may result from eating; Neg Relief = anticipation of relief from negative states and feelings as a result of eating; Lack Control = lack of control over eating; Thoughts = thoughts or preoccupation with food; Hunger = craving as a physiological state; Emotion = emotions that may be experienced before or during food cravings or eating; Environment = cues that may trigger food cravings; Guilt = guilt from cravings and/or for giving into them.